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ADOPTIVE CELL TRANSFER: EXAMINING THE POTENTIAL OF A T CELL-
MEDIATED THERAPY FOR METASTATIC MELANOMA  
MEHWISH IMDAD SEEHAR 
ABSTRACT 
  
Adoptive cell transfer techniques identify and isolate patient anti-tumor lymphocytes in 
vitro followed by ex vivo expansion of these tumor specific T cells. Identification and 
isolation of lymphocytes from patient tumors allows for the selection of anti-tumor 
lymphocytes that are highly specific for individual tumor antigens. Furthermore, 
recombinant technology allows for engineering of chimeric antigen receptors (CARs) 
which allow these T cells to target multiple tumor antigens. Techniques involving ex vivo 
growth lead to a 1,000- to 5,000-fold increase in numbers of lymphocytes. Cultured 
lymphocytes can then be infused via IV and growth maintained with administration of 
exogenous IL-2. Cancer patients are then monitored for both immunological activity as 
well as any adverse cytokine reactions. We looked at several trial studies for the 
application of adoptive cell transfer in metastatic melanoma compare the efficacy of the 
regimen to other established melanoma treatments. Adoptive transfer has proven to be 
effective for patients with late stage melanoma, however, the aim of this study was to 
examine some of the challenges in creating an effective standard protocol for adaptation 
in clinical settings, including difficulty in obtaining significant cell populations from 
tumors, challenges in the proliferation of these tumor-infiltrating lymphocytes (TIL) and 
  v 
determination of antigen-specificity, i.e. facilitation of a simplified and quicker approach 
to the therapy.  
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INTRODUCTION 
 
Despite being one of the most rare skin cancers, malignant melanoma accounts 
for the highest number of skin cancer deaths (Svane and Verdegaal 2014). The incidence 
of melanoma, in situ and invasive, has shown a continuous upward trend since the 1970s 
at an annual rate of 2.6% (Higgins II, Lee, Galan, & Leffell, 2015). Similarly, the risk of 
developing melanoma has gone up more than 20 fold with recent data indicating that 
approximately 1 in 100 people will be diagnosed with melanoma. 2001 data gathered by 
the American Joint Committee On Cancer (AJCC) found a significant decrease in 
survival rates correlated with cancer staging (See Figure 1). Additionally, 2015 
Surveillance, Epidemiology, And End Results (SEER) data indicate that the prognosis for 
those with late stage melanoma was poor at an approximate survival rate of 16% 
(“Melanoma of the Skin - SEER Stat Fact Sheets” 2016).  
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Figure 1: Fifteen year survival rates comparing local melanoma at stage I and II to 
regional and distant metastasis at stage III and stage IV. Staging was done using 
TNM Classification Of Malignant Tumors (TNM) and analysis was based on data 
obtained from the American Joint Committee On Cancer AJCC.  
Source: (Balch CM, et al. 2001) 
Stratification of data indicates a disproportionate rate of melanoma in younger 
patients as well as in males (Higgins II et al. 2015a). As a result, mortality rates in the 
general population have been skewed with a higher rate of male mortality from malignant 
melanoma (Berwick et al. 2016). It is difficult to fully establish true incidence rates given 
that early screenings may play a role in the increased reported incidence. SEER studies 
have found that biopsy rates have doubled and have postulated that the increase in 
melanoma diagnoses parallels this change (Higgins II et al. 2015a). 
Sun exposure is an established major environmental risk factor responsible for 
melanoma development in up to 90% of cases (Berwick et al. 2016). Melanoma risk has 
also been associated with a geographical spread encompassing larger incidence rates in 
Europe, Australia, and the United States (Higgins II et al. 2015a) reflecting the amount of 
ambient sun exposure of the population (Rommens et al. 2016). Exposure has been 
characterized as intermittent (short, intense exposure) or chronic. Cohort and case-control 
studies have found that intermittent exposure is tied to increased melanoma risk and that 
chronic exposure has a weaker association potentially offset by epithelial thickening 
(Berwick et al. 2016). Sunburn, especially in early childhood, has been strongly 
associated with increased skin cancer rates in adulthood. In adults, this risk and exposure 
is increased. In particular, an increase in tanning has been shown to contribute to 
increased risk (Kroon, Morton, and Thompson 2004). Other environmental exposures 
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associated with increased risk of melanoma include carcinogens such as pesticides, 
herbicides, and dyes.  
Another major indicator of risk is the presence and type of nevi. Nevi are benign 
clusters of melanocytes and have been implicated in several studies to be associated with 
an increased risk of skin cancer. The size of these nevi is also correlated with melanoma 
risks. Finally, dysplastic nevi often serve as precursors to the development of melanoma. 
Today, screening and preventative public health measures rely on recognition of 
dysplastic phenotypes based on shape, color, and diameter (Berwick et al. 2016).  
Current therapeutics for an early diagnosis of malignant melanoma include 
surgery and monitoring, while late stage therapeutics often involve supplemented 
adjuvant therapies in addition to surgical intervention. These adjuvants include 
chemotherapies, BRAF/MEK inhibitors, and in recent years, immunotherapy (Higgins II 
et al. 2015b; Eggermont, Spatz, and Robert 2014). 
Multiple immunotherapeutics are currently being studied for their efficacy in 
treating melanoma as well as other cancers such as acute lymphoblastic leukemia (ALL). 
These therapeutics consist of vaccines administered after the diagnosis of melanoma as 
well as a number of biologics, including different types of IFNs and interleukins (Davey, 
van der Westhuizen, and Bowden 2016). Monoclonal antibody biologics targeting cell 
cycle checkpoints have been found to be effective in treatment of malignant melanoma. 
Currently, checkpoint blockade therapy is at the forefront of melanoma treatment with 
several FDA-approved drugs on the market for patients with metastatic melanoma (Susan 
Swetter 2016). An immunotherapy technique called adoptive cell transfer (ACT), which 
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focuses on harnessing tumor-infiltrating lymphocytes from patients, has shown 
therapeutic promise in patients who have not responded to other established treatment 
modalities (see Figure 2).  
Early studies examined the efficacy of ACT using both ex vivo tumor tissue 
cultures as well as animal models. Using these models, a therapeutic protocol was 
established which found that treatment with chemotherapy prior to cell transfer could 
boost the effectiveness of cell transfer therapy (Steven A. Rosenberg and Dudley 2009). 
Initial studies in patients using these techniques have been limited to Phase I and II 
clinical trials, however, response rates in these trials have been promising. One study 
found that administration of high dose total body irradiation followed by cell transfer had 
a response rate of 72%, as measured by the Response Evaluation Criteria In Solid 
Tumors (RECIST), in comparison to administration of chemotherapeutic drugs followed 
by transfer showing a rate of 52% (Steven A. Rosenberg and Dudley 2009). Many 
patients were found to have responses that lasted up to, and beyond, three years with a 
smaller cohort showing complete responses that were ongoing at the time of the report. 
These responses ranged anywhere from 18 to 36 months (Steven A. Rosenberg and 
Dudley 2009). Regression was noted in all sites of metastases including brain and bone. 
(Steven A. Rosenberg and Dudley 2009) 
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Figure 2: Patient survival rates following ACT therapy. Comparison of survival 
rates following total body irradiation, chemotherapy, and control group response. 
Patient response of joint therapy with total body irradiation shows promising 
potential as a combinatorial regimen, however, further randomized trials are 
necessary to assess efficacy of the treatment.  
Source: (Steven A. Rosenberg and Dudley 2009)
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OBJECTIVES 
The primary aim of this study is to provide a comprehensive review of the techniques and 
efficacy of ACT as a potential novel therapy for malignant melanoma and the impact of 
the trials on other non-melanoma cancers. In addition to this, the study will compare the 
new technique and its impact with previously established modalities for cancer treatment. 
Specifically, the study will examine the establishment of ACT in cancer treatment as a 
future standard of care. We believe that adoptive cell transfer therapy provides a 
promising avenue for cancer therapy in late stage (III and IV) melanoma cases where 
other therapies have failed. We will analyze trial studies on adoptive transfer methods to 
compare remission rates with administration of autologous lymphocytes selected for 
antigenic properties with standard melanoma therapies in order to evaluate survival rates 
of late stage melanoma patients.  
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HISTOLOGY OF MELANOCYTES 
The skin is divided into three layers: the epidermis, dermis, and hypodermis. 
Melanoma is classified as a cancer of melanocytes which reside in the topmost layer of 
the skin, the epidermis. The epidermis itself consists of five cellular layers from the 
outermost layer, stratum corneum, which is exposed to the environment to the stratum 
basale which is adjacent to the dermis (see Figure 3). Melanocytes are found in the 
stratum basale and make up about 8% of epidermal cells. They produce a pigment called 
melanin which is derived from DOPA and bound to a protein. This melanoprotein is then 
transferred via vesicles called melanosomes and phagocytosed by surrounding 
keratinocytes (Kroon, Morton, and Thompson 2004).  
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Figure 3: Normal skin structure with layers of the epidermis and dermis. The figure 
above illustrates the location of melanocytes relative to other layers of the skin as 
well as proximity to vessels.  
Source: (Farage et al. 2007) 
 
Melanin serves a protective barrier to UV DNA damage by forming a barrier over 
the nucleus. Regardless of race, each human being has the same number of melanocytes 
however, variation in the amount of pigment produced, the size of melanosomes, and the 
aggregation of the melanin produces variation in skin color. UV exposure tends to 
increase the amount of melanin through mechanisms that upregulate production in 
response to UV damage (Kroon, Morton, and Thompson 2004).  
Histologically, melanoma has two growth phases: radial or horizontal growth and 
vertical growth (see Figure 4). Initial growth can be classified as melanoma in situ with 
melanocyte proliferation being restricted to the epidermis. Radial growth is considered 
intraepidermal and microinvasive (Higgins II et al. 2015b). Microinvasion refers to 
melanocyte proliferation and invasion of the papillary dermis either as nests of cells or 
singularly (Kroon, Morton, and Thompson 2004). At this point, the melanoma does not 
have the capacity for metastasis due to lack of access to lymphatic channels. Further 
growth into the subsequent skin layers is classified as vertical growth at which the point 
the melanoma has capacity for metastasis. Histologically, this phase is characterized by 
presence of sheets and/or large nests of cells in the dermal layer of the skin.  
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Figure 4: The figure diagrams both the histological progression of melanoma and its 
movements through the different growth phases beginning initially as a benign 
nevus and moving through radial and horizontal growth to ultimately metastasize. 
Common DNA mutations contributing to the growth are also noted and will be 
discussed further under therapies.  
Source:  (Arrangoiz et al. 2016)
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The most common histological pattern of melanoma is characterized as superficial 
spreading melanoma. This type of histology is seen in at least two-thirds of melanoma 
cases but could be as high as 75% (Higgins II et al. 2015b). In the epidermis this type of 
spreading is seen as poor circumscription of melanocytes, aberrant distribution of 
melanocytes, and the presence of melanocytes above the basal layer, i.e. pagetoid spread 
(Kroon, Morton, and Thompson 2004). Often spreading is haphazard and distributions 
can vary leading to either the presence of melanocytic nests, or the presence of single 
melanocytes spread over a large area. These nests often lack cohesion due to lack of 
desmosomal attachments. The cells themselves generally have a large eosinophilic 
cytoplasm with multiple nucleoli, often hyperchromatic with the presence of mitotic 
activity, and are characterized by lack of maturation (Higgins II et al. 2015b). As these 
melanocytes migrate towards the papillary dermis, they begin to shrink losing both 
cytoplasm and nucleoli.  
A second common type of melanoma is nodular melanoma found to be more 
common during middle-age and often occurring around the trunk. While it shares similar 
cytological features with superficial melanoma, one prominent feature is that unlike 
superficial melanoma, nodular melanoma is well circumscribed (Higgins II et al. 2015b). 
This subtype lacks lateral spread and is often ulcerated. Since it bypasses lateral spread, 
this type of melanoma is correlated with aggressive growth and higher rates of metastasis 
(Higgins II et al. 2015b).  
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ETIOLOGY AND PATHOGENESIS 
ENVIRONMENT  
In 2004, Meyskens et al. proposed a pathogenesis pathway for melanoma 
development due to sun exposure. The team hypothesized that generation of radical 
oxygen species served as a key factor in the initiation and proliferation of melanoma. It is 
known that melanin has a variety of redox properties and Meyskens, et al. proposed that 
the key to melanoma pathogenesis was in the redox-recycling of this molecule (see 
Figure 5). Initial studies postulated that a source of exogenous oxidative stress will create 
a signal for radical oxygen species (ROS) development in melanocytes and melanoma 
cells. The study also proposed that this reaction to oxidative damage differed from typical 
oxidative stress in non-pigmented cells. One experiment found that the addition of 
superoxide dismutase, which normally serves as an antioxidant in protecting cells from 
reactive O²-, to melanoma cultures resulted in an enhanced stress signal (Meyskens, 
Farmer, and Anton-Culver 2004). In contrast, addition of superoxide dismutase had no 
negative effect on melanocytes. Further examination found increased levels of 
intracellular superoxide anions in melanoma cells compared to melanocytes (Meyskens, 
Farmer, and Anton-Culver 2004). From these and previous studies, it is believed that 
melanin in this context functions as a pro-oxidant.  
In conjunction with these, and previous other, studies on the progression of 
melanoma, a proposed pathway was set out as follows: 
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i) Oxidation of synthetic melanin due to UV damage, normal metabolism, or 
inflammatory responses increases its affinity for metal ions due to 
tautomerization of a quinone-imine 
ii) Accumulation of metal ion(s) and other chemicals then promotes redox 
recycling 
iii) This increased accumulation exhausts cellular anti-oxidant stores and 
machinery 
iv) Depletion of anti-oxidants serves as the final step for DNA damage via free 
radicals and ROS.  
Normally uptake of metals is regulated by enzymes known as metallothioneins. In 
addition to the carcinogenic role played by heavy metals such as Cu, Fe, Mn, and Co, it is 
believed that polymorphisms in the metalliothioneins could potentiate genetic risk to 
cancer (Meyskens, Farmer, and Anton-Culver 2004). Additional nonmetals such as 
herbicides, pesticides, organic amines, and dyes have also been identified as contributors 
to the pathogenesis of cancer.  
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Figure 5: Mechanism of Melanoma Pathogenesis 
Figure illustrates the proposed mechanism through which normal redox cycling 
mechanisms become overwhelmed and lead to DNA damage of melanocytes.  
Source: (Meyskens, Farmer, and Anton-Culver 2004) 
 
GENETIC 
 Melanoma studies have found that mutations in BRAF are one of the earliest 
contributing factors to melanoma development. Forty to 50% of melanomas have a 
mutation in BRAF which activates the MAPK pathway activating telomerase and 
disrupting the normal cellular G1-S checkpoint (Eggermont, Spatz, and Robert 2014; 
Hugdahl et al. 2016). Shain et al. found that the majority of benign lesions harbored a 
BRAF V600E mutation. No other mutations were associated with melanoma risk in this 
study and it was concluded that the singular mutation was sufficient for nevus formation. 
Further studies found that lesions that did not have mutations in the V600E of BRAF but 
had other BRAF mutations or NRAS mutations were the result of multiple oncogenic 
alterations rather than a single event. The most common secondary mutation found was 
that of TERT. Other mutations common to melanoma include CDKN2A, p53, and Rb 
(Eggermont, Spatz, and Robert 2014).  
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PROGNOSIS 
Despite being a more aggressive form of cancer, most early forms of melanoma 
are curable with surgery. SEER data indicated that 84% of melanomas are caught early 
and 5-year survival rates were around 98%. However, stage IV metastatic melanoma 10-
year survival rates are less than 10% and despite increased understanding of the disease, 
new therapies have yielded mixed results during late stage cancer. Additionally, 
progression or recurrence in the future are also liable to influence these survival rates. 
Studies have found that the average time for localized cancer to metastasize is about 28 
months (“Melanoma of the Skin - SEER Stat Fact Sheets” 2016). Common sites for this 
metastasis included the bone, brain, and liver. Finally, a third of melanoma patients 
experience recurrence in the future.  
Currently, the standard of care for most patients continues to be dacarbazine 
though tumor response rates have varied from 6% to 20% with a duration of 6 months 
(Kim et al. 2010). A primary factor influencing survival that has been studied is the site 
of metastasis. AJCC analysis of the melanoma database studied patient survival rates and 
found that patients with distant metastases had a better prognosis if metastasis was in the 
skin and subcutaneous tissue (Balch et al. 2009). Patients with pulmonary metastasis had 
an intermediate prognosis and those with metastasis of any other visceral sites had the 
worst prognosis (Balch et al. 2009).  
One melanoma biomarker which has been noted since 1954 is elevated serum 
lactate dehydrogenase (LDH) which serves as an indicator for liver metastasis . 
Abnormal LDH levels have been associated with decreased survival and could be 
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significant for monitoring during late-stage malignant melanoma (Gogas et al. 2009). 
Other significant biomarkers include increased S100B, a calcium binding protein found 
cell cytoplasms, correlating with disease progression. Subsequently, low S100B could be 
utilized to measure a positive response to treatment (Gogas et al. 2009).  
  
CURRENT TREATMENTS 
SURGERY 
 Surgery, particularly in early stage melanoma, has proven to be an effective tool 
for treatment of melanoma in situ, and as previously mentioned, was correlated with a 
high survival rate if the cancer was localized (Susan Swetter 2016). Multiple techniques 
for excision are used in removal depending on the staging of the cancer and the site of the 
lesion. Wide-local excision focuses on lower risk body site and is used for early stage 
cancer (Higgins II et al. 2015b; Davey, van der Westhuizen, and Bowden 2016). Skin 
cancer tissue and a smaller margin of healthy tissue (0.5 cm) is removed and the samples 
are sent for further processing. In contrast, Mohs surgery will often remove visible skin 
cancer along with layers of skin and adjacent soft tissue in an effort to excise the totality 
of the cancer in the epidermal and dermal layers (Susan Swetter 2016). Finally, a staged 
excision will use surgical removal along with sectioning and analysis to identify margins. 
This immediate section analysis is then used to determine if further removal is necessary 
or whether margins have cleared. Wound closure in this case is delayed until a negative 
margin is confirmed (Eggermont, Spatz, and Robert 2014).  
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TOPICAL THERAPY 
 Currently, FDA approval for the drug imiquimod is limited to superficial basal 
cell carcinoma, actinic keratosis, and genital warts (Ellis et al. 2012). It is unknown if the 
FDA is currently investigating its potential application for melanoma in situ. 
Nevertheless, it has been used as an off-label drug for the treatment of melanoma because 
of its properties as an immunotherapeutic. The drug works by activating toll-like receptor 
7 which leads to an immune response at target sites. Efficacy of the drug has been 
variable with responses ranging from 0 clearance to 100 percent.(Fan et al. 2015; Ellis et 
al. 2012) In addition, since no standardized guidelines have been set for dosage, regimens 
have been variable. Currently, it is difficult to identify the significance of the drug in 
treating melanoma.  
 
CHEMOTHERAPY 
Dacarbazine  
Dacarbazine is considered one of the primary chemotherapeutic drugs for 
melanoma treatment, is the only chemotherapeutic agent approved for melanoma, and 
functions as an alkylating agent (BHATIA, TYKODI, and THOMPSON 2009). Despite 
being the standard of care, response rates from studies are variable. Retrospective 
analyses of randomized trials compared results from patients administered dacarbazine 
with non-dacarbazine treatments (Lui et al. 2007). Dacarbazine administration revealed 
an objective response rate of 15% with the majority of patients having a partial response 
at 11.2% (BHATIA, TYKODI, and THOMPSON 2009) Only a small percentage of 
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patients were able to sustain these responses and 5-year survival rates were found to be 
2% (Lui et al. 2007; BHATIA, TYKODI, and THOMPSON 2009). In addition, the drug 
is associated with typical chemotherapeutic toxicities such as nausea, fatigue, and 
myelosuppression (BHATIA, TYKODI, and THOMPSON 2009).  
Temozolomide 
 An oral analog of dacarbazine, temozolomide, has the advantage of increased 
bioavailability as well as access to the CNS which is promising for cases of brain 
metastases. A phase III randomized study compared survival and response rates in 
patients with metastatic melanoma who received temozolomide to those receiving 
dacarbazine and found no statistically significant differences (Middleton et al. 2000). In 
the Middleton study, oral temozolomide was administered 5 days every 30 days or 
dacarbazine 5 days every 21 days. A second multi-center study compared dacarbazine 
(10%) administration response rates to temozolomide (14%) and also found no 
significant differences in survival rate (Patel et al. 2011).  Oral temozolomide was 
administered for seven days every two weeks or dacarbazine administered intravenously 
every three weeks.  
Combination Chemotherapy 
 A drug cocktail known as the Dartmouth regimen combines cisplatin, 
dacarbazine, BiCNU, and tamoxifen (CDBT) (BHATIA, TYKODI, and THOMPSON 
2009). Initially, response rates were reported to be between 40 and 50% however, later 
multicenter RCTs did not show a significant different in survival when compared to 
control therapy with dacarbazine (P. B. Chapman et al. 1999). Patients with stage IV 
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melanoma were randomly assigned to either the Dartmouth regimen or standard 
dacarbazine and were observed for tumor response, survival time, and side effects. Other 
cocktails with vinblastine has shown a 40% increase in phase II trials however, many of 
these combinations have a greater toxicity and do not significantly alter the response or 
survival rates (McDermott et al. 2000; Legha et al. 1996). Stage IV patients in these 
phase II trials were given a mix of cisplatin, vinblastine, and dacarbazine and tumor 
response as well as survival measured (McDermott et al. 2000).  
Intravenous Limb Perfusion  
 One technique, limb perfusion, have emerged as an effective way to deliver 
chemotherapy drugs while bypassing adverse systemic effects. The technique essentially 
creates a circuit between the vasculature of the tissue and an ex vivo system, similar to a 
dialysis or plasmapheresis machine, allowing for drugs to only travel along the vessels of 
the target tissue. Early trials have found response rates from 30-60% (Maverakis et al. 
2015; Cumberlin et al. 1985) with increased responses of up to80% in conjunction with 
TNF and IFNγ (Maverakis et al. 2015). Addition of cytokine factors like TNF and IFNγ 
have been found to increase response rate significantly (Maverakis et al. 2015). Patients 
were randomly assigned to a group administered either melphalan or the IFN/TFN 
combination using isolated limb perfusion and response rates were measured using 
RECIST criteria (Cornett et al. 2006).TNF addition yields a 68.9% response rate where 
melphalan alone showed a 46.5% response (Maverakis et al. 2015; Cornett et al. 2006). It 
has been difficult however, to assess survival rates beyond initial response without proper 
comparative trials and as a result the technique needs further study.  
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BRAF/MEK Inhibition 
 The BRAF gene is found mutated in 40-70% of melanomas and encodes for a 
Ser/Thr kinase that is part of the MAP kinase pathway (Davies et al. 2002) . The mutation 
leads to activation of, and uncontrolled, cell growth (Hugdahl et al. 2016). Inhibitors of 
BRAF such as Vemurafinib and Dabrafenib are specific to the V600E and V600E/K 
mutations respectively. In comparison to the standard of care, dacarbazine, Vemurafinib 
was found to have better response rates (Paul B. Chapman et al. 2011). A multi-center 
study with patients in stage IIIC or IV melanoma positive for the V600E mutation was 
conducted. Patients were randomly assigned to either Vemurafenib or dacarbazine and 
tumor clearance measured using RECIST criteria (Paul B. Chapman et al. 2011). Initial 
studies found that 6-month response rates to BRAF inhibition were around 86% 
compared with 64% for dacarbazine (Paul B. Chapman et al. 2011; Maverakis et al. 
2015). In addition, survival time was lengthened by three times as much. Other studies 
found 1-year survival rates to be around 64% for BRAF inhibitors in comparison to 
dacarbazine at 42% (Maverakis et al. 2015).  
MEK is another signaling protein found downstream of the BRAF pathway. 
Inhibitors of MEK (cobimetinib or trametinib) in conjunction with BRAF inhibitors have 
proven to be more effective than BRAF inhibition alone (Maverakis et al. 2015). 
Comparison of the joint therapy with other immunology-based therapeutics such as 
monoclonal antibody administration found that BRAF/MEK inhibitor regimens had 
higher overall and progression-free survival (Long et al. 2014). Patients with stage IIIc or 
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stage IV melanoma with BRAF V600E or V600K mutations were enrolled and 
randomized into two groups. One group was administered BRAF/MEK combination 
drugs while the second was administered BRAF and a placebo. Efficacy of treatment was 
gauged with progression-free survival as well tumor response rates. Overall response rate 
was 67% in the combination group versus 51% (Long et al. 2014).  
CTLA4 Inhibitors 
 The T-cell CTLA4 receptor normally functions to prevent or down regulate the 
immune response. Binding of the B7 receptor on antigen-presenting cells to the CTLA-4 
receptor of T-cells is a specific mechanism that serves as a checkpoint for the immune 
system. Cancer cells can take advantage of this process by inhibiting T-cell proliferation 
by expressing B7 receptors and binding T-cell CTLA-4 receptors thereby initiating a 
false down regulation response. Administration of antibodies to CTLA4 allows for 
unopposed T-cell activation and proliferation against tumor antigens (Maverakis et al. 
2015). These free antibodies serve to bind the CTLA-4 without activating a down 
regulating response. Antibodies bound to CTLA-4 receptors block tumor cell B7 
receptors from inhibiting the immune response. Tremelimumab, a first generation 
monoclonal antibody, was found to demonstrate anti-tumor activity in late stage (IIIC or 
IV) melanoma patients (Camacho et al. 2009) though later trials comparing the drug to 
standard of care did not demonstrate significant difference in survival rates (Ribas et al. 
2013). However, a similar drug ipilimumab, was found to prolong survival rates when 
administered alone or in conjunction with a peptide vaccine (Hodi et al. 2010). A cancer 
vaccine comprised of HLA-0201 restricted peptides from the gp100 protein individually 
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does not have strong anti-tumor effects, however, Hodi et. al examined the effects of 
gp100 in conjunction with ipilimumab. Stage III and IV patients were separated into three 
groups with one group receiving gp100 vaccine with ipilimumab, a second group 
administered ipilimumab along with a gp100 placebo, and a third group given gp100 with 
an ipilimumab placebo. Risk of progression was reduced by 19% in the group co-
administered ipilimumab with gp100 and the group administered ipilimumab alone was 
found to have a 36% overall response based on RECIST (Hodi et al. 2010).  One side 
effect of these medications is adverse immune cytokine-related events such as rashes, 
vitiligo, as well as gastrointestinal events such as diarrhea.   
 
PD1/PDL1 Inhibitors 
 PD1 is a receptor found on activated T-cells, B-cells, and myeloid cells and is 
involved in modulating the T-cell response. Generally, binding of the PD1 of the T-cell 
with its ligands on cells such as antigen-presenting cells is considered inhibitory. Several 
cancers have mutations that allow for expression of PD1 ligands. This helps cancers 
evade the natural immune response by binding PD1 ligand with the PD1 receptor of T-
cells. Therefore, antibodies against either ligand can block inhibition of T-cell and serve 
to increase T-cell activation and proliferation. Therapies combining nivolumab (anti-
PD1) and ipilimumab (anti-CTLA4) show therapeutic promise however, trials are still 
ongoing and efficacy is difficult to assess (Wolchok et al. 2013; Tsai and Daud 2015). 
Nivolumab is a monoclonal antibody that blocks the PD1 receptor and prevents T-cell 
inhibition by the cancer (Maverakis et al. 2015). A second drug, pembrolizumab (anti-
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PD1) was given FDA approval after a recent study found that response rates were around 
26% (Robert et al. 2014). Phase I trials conducted by Robert et. al selected for patients 
(n=173) who had undergone previous therapy with ipilimumab and had disease 
progression. Pembrolizumab was intravenously administered and response rates were 
measured based on RECIST.   
IL-2 Therapy  
Administration of intravenous IL-2 promotes T-cell proliferation (Yamamoto, 
Ueta, and Osaki 2003). Data from several clinical trialsfound that a IL-2 could produce 
responses in patients who had failed to respond to previous therapies (Atkins et al. 1999; 
Weide et al. 2010). Patients with metastatic melanoma were administered intravenous 
infusions and monitored through multiple cycles. In metastatic melanoma, IL-2 delivery 
has a moderate response of 16% (Atkins et al. 1999), however, the side effects of IL-2 
therapy can often be a barrier to effective treatment. Intravenous IL-2 can lead to vascular 
leak syndrome (VLS) and toxicities with symptoms resembling septic shock (Atkins et al. 
1999). Therefore, it is limited to a small population of individuals (Maverakis et al. 
2015). Intralesional administration of IL-2 has also been studied and has shown responses 
ranging from 40-70% (Radny et al. 2003; Boyd, Wehrli, and Temple 2011). Radny et. al 
enrolled patients with stage III or IV melanoma and monitored response rates to weekly 
intralesional injections of IL-2. Boyd et. al utilized a similar method and evaluated 
patients using RECIST criteria. Both studies found significant clearance rates. Multiple 
studies have shown strong response rates with biweekly administration of high dose IL-2 
in combination with imiquimod. Green et. al recruited patients who were at stage III and 
 23 
IV of melanoma where the cancer had failed to respond to other treatment modalities. 5% 
imiquimod was applied topically for 4 weeks and was followed by three regimens of 
intravenous IL-2 (Green et al. 2007). A total of 182 lesions was treated and responses 
seen in approximately 50% with a complete response in 40.7% of lesions (Green et al. 
2007). 
IMMUNOLOGICAL MECHANISMS OF MELANOMA 
It has been noted that a subset of melanomas undergo spontaneous regression, 
partial or full (Kroon, Morton, and Thompson 2004). In up to 10% of patients with 
metastasis, no evidence of a primary tumor was found (Requena et al. 2009). Given that 
there is a possibility of regression before the melanoma is diagnosed, regression may be 
underreported. Partial regression is more common and can be found in up to 50% of 
melanoma patients although it is likely underreported as well (Kroon, Morton, and 
Thompson 2004).  
Histological features that can be used to identify regression rely on tumor cell 
“clumps” found in the dermis that result from lymphocyte infiltrates (Smoller 2006). 
Specifically, the immune response causes tumor cell areas to become less cohesive and 
disparate. The events that mediate spontaneous regression are immunological; a direct 
result of increased T-cell response. Specifically, it was found that tumors with regression 
events had an increase in the number of activated CD4+ T cells (Printz 2001). Early stage 
melanoma had a higher concentration of CD4+ T cells whereas advanced melanoma had 
a higher concentration of CD8+T cells.  
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Studies using RT-PCR found that a large majority of melanomas showed 
increased IL-2 and Th1 cell concentrations. Classification of 285 patients into subsets 
based on the magnitude of T cell infiltration found that increased infiltration of tumor 
tissue was correlated with survival rates (Clemente et al. 1996). Histological sections 
were obtained from  patients enrolled in the WHO Melanoma Study Group. Clemente et. 
al used Elder and Clark criteria to classify infiltrates into brisk, non-brisk, and absent 
categories. “Brisk” infiltrate was defined by lymphocyte presence throughout the vertical 
growth phase whereas “non-brisk” infiltrate was identified if lymphocytes were located 
as foci in the vertical growth phase. Five-year survival rates for higher infiltration was 
77% as compared to a 53% survival rate for “non-brisk” infiltration (Clemente et al. 
1996). Therefore, the concentration of immune lymphocytes can be used a factor to 
measure prognosis of melanoma.  
Laboratory studies in the early 1980s noted the presence of immune cells, 
lymphokine-activated killer (LAK) cells, that targeted malignant cells and hypothesized a 
future application of these CTLs for in vitro development of a strengthened immune 
response (Yang and Rosenberg 2016). Il-2 administration in conjunction with culturing 
lymphocytes with their autologous tumor stimulated peripheral lymphocyte proliferation 
(Topalian, Solomon, and Rosenberg 1989). Rosenberg et. al noted that IL-2 induction of 
peripheral blood mononuclear cells (PBMC) could generate LAK cells that targeted 
tumor cells. These initial cells were hypothesized to be related to NK cells (Steven A. 
Rosenberg 2014). These initial trials removed NK cell precursors from patients with 
melanoma at stage III and IV following an intravenous course of IL-2. Cells were then 
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further proliferated with IL-2 and administered to patients. These lymphocytes were 
shown to lyse tumor lines and more specifically, were found to be prevalent in melanoma 
patients. Another benefit was that these lymphocytes could potentially be harvested from 
patient surgical specimens. These studies using NK  cells led to alternative therapeutic 
strategies utilizing tumor antigen specific T lymphocytes. This approach takes advantage 
of the fact that tumors will contain anti-tumor T-cells which, even if weakly response to 
tumor antigens, can potentially be harnessed and modified to provide stronger therapeutic 
potential.  
 Studies in the mid-1980s found that culturing IL-2 with tumor infiltrating 
lymphocytes had an anti-tumor effect which was tumor specific and had an efficacy that 
was 50-100 greater than previous NK cell therapeutic responses (Spiess, Yang, and 
Rosenberg 1987). Tumor cell suspensions were cultured with IL-2 and cells 
demonstrating anti-tumor activity were expanded , transferred into tumor-bearing mice, 
and metastases was measured for reduction.  
One of the most notable findings from this study was that there was a stronger 
response observed in advanced melanoma tumors. Primary phase I trials done by 
Rosenberg et al. found a correlation with previous animal studies in terms of regression 
of metastases . The initial trial included 20 patients with pulmonary metastases who were 
administered cyclophosphamide followed by TIL and IL-2. Of the 20, 11 patients had 
complete or partial tumor responses (S. A. Rosenberg et al. 1988). A later follow-up trial 
with 86 patients found a similar response rate in patients with metastatic melanoma (S. A. 
Rosenberg et al. 1994). In the follow-up trial, TIL with IL-2 was administered in two 
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cycles separated by 2 weeks. Of these 86 patients, 57 received cyclophosphamide before 
the initial infusion of TILs. Objective response rates in patients receiving TIL/IL-2 was 
31% while those receiving cyclophosphamide prior to transfer had a response rate of 35% 
based on RECIST (S. A. Rosenberg et al. 1994).  
 
MATERIALS AND METHODS 
Although the idea of adoptive cell transfer therapy showed promise, several issues 
needed to be evaluated before it could be classified as a widespread and efficient standard 
treatment. The primary necessity was the establishment of a standard protocol for 
administration. First, this required trials that could create a standard and successful 
method for extracting, establishing, and expanding cultures. Secondly, the treatment 
modality had to be able to identify and evaluate the specificity of cultured cells in 
targeting tumor antigens. Finally, it required assessment of toxic side effects common to 
many immunological treatment methods. In the case of adoptive transfer, the major factor 
would be toxic effects of IL-2 or other adverse cytokine events.  
Standard treatment protocols at this point follow a linear progression that is as follows: 
1. Extraction of autologous tumor-infiltrating lymphocytes from patients 
2. Lymphodepletion with chemotherapeutic agents 
3. In vitro cultivation and expansion of tumor-infiltrating lymphocytes specific for 
tumor antigen 
4. Transfer of TIL to patients with subsequent systemic IL-2 administration 
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The following analysis examines the studies that evaluated the feasibility of each step and 
the efficacy of each step in treatment of metastatic melanoma.  
 
Melanoma-associated antigens 
MART-1 and gp100 are two of the most common melanoma proteins that can be 
targeted during therapy. Melan-A, also labeled as MART-1, is a protein normally 
expressed in melanocytes as well as in a large majority of melanomas (Khammari et al. 
2009). This marker is especially useful for distinguishing melanocytic tumors from non-
melanocytic neoplasms and has both high immunogenicity and expression on melanoma 
cells (Gogas et al. 2009). The MART-1 protein is a melanocyte specific marker that 
serves as an antigen for CTLs particularly for metastatic melanoma and is a useful target 
of immunotherapy. This type of immunotherapy, however, has a potential autoimmune 
effect which can lead to the destruction of healthy melanocytes resulting in vitiligo.  
HLA-A2  
 HLA is involved in the presentation of antigenic peptides to CD8+ CTLs. A large 
number of human tumors have been found to have reduced expression of HLA-I antigens 
(Pandolfi et al. 1991). A variant of HLA, HLA-A2 (HLA-*02), has been associated with 
a stronger immune response towards melanoma cell lines in animal studies (Pandolfi et 
al. 1991). This variant, HLA-A2, was originally identified by Wolfel et. al., and studies 
by Darrow et al. confirmed that HLA variants play a role as a restricting element for lysis 
of several melanoma-associated antigens (Wölfel et al. 1994; Darrow, Slingluff, and 
Seigler 1989). Specifically, HLA-A2 variants contain restriction elements that 
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preferentially generate CTLs that are more reactive against autologous melanoma 
antigens.  
Changes in the expression of HLA-A2 have also been observed in several 
cancers. It is hypothesized that loss of HLA-A2 expression contributes to metastatic 
progression by allowing cells to escape immune surveillance specifically via bypassing 
CTL cytotoxicity (Pandolfi et al. 1991). Specifically, expression of the HLA-*0201 allele 
has been noted to be significant for ACT. Several studies have found that expression of 
HLA-A2 is crucial for T-cells to recognize melanoma tumor antigens, though it has been 
posited that HLA variants may be key in other cancer therapies as well. Experiments 
done by Pandolfi et al. derived TIL and melanoma lines from 4 HLA-A2+ patients. Of 
these, HLA-A2 expression was lost in 2 of the 4 melanoma lines and this loss of 
expression was correlated with decreased immunological recognition by lymphocytes. 
Additionally, it was noted that TIL derived from patients whose melanoma lines were 
HLA-A2+ had a CD8 phenotype and had the capacity to lyse the melanoma cells 
(Pandolfi et al. 1991). It was found that patients whose melanoma lines had lost HLA-A2 
expression had a CD4 phenotype and did not have cytotoxic activity (Pandolfi et al. 
1991).  
T2 cell lines  
 In order to introduce a specific antigen prior to cell culture expansion, T2 cell 
lines can be used. Normally, MHC I antigen presentation relies on peptide transport from 
the cytoplasm to the endoplasmic reticulum or Golgi via the transport-associated with 
antigen presentation transporter (TAP). T2 cell lines are TAP-deficient, however absence 
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of ER peptides in these deficient cells leads to a greater than normal amount of MHC I 
complexes lacking peptides in the ER and Golgi as well as on cell surfaces (Luft et al. 
2001). Not only can these MHC I complexes on the surface be loaded with available 
peptides, but studies by Day et al. found that there is a TAP-independent route which 
allows cells to internalize exogenous peptides (Day et al. 1997).   
 Additionally, Luft et al. found that certain specific peptides have greater binding 
specificity for MHC I complexes in melanoma patients. An HLA-A*0201-restricted 
MelanA peptide can have either the AAG sequence (AAGIGILTV), which has low 
affinity for MHC I complexes, or the EAA sequence (EAAGIGILTV) which has high 
affinity. The AAG sequence required MHC synthesis and transport for antigen 
presentation, but the ELA does not. Instead, the ELA sequence can replace peptides from 
preformed complexes. Finally, it was also noted that ELA sequences had a longer 
duration of antigen presentation (Luft et al. 2001).  
 Anti-tumor response was also noted for both peptide sequences. Peptide-specific 
CTLs generated using either the AAG sequence or ELA sequence were tested for 
specificity and cytotoxicity against melanoma cell lines. Both lines were capable of 
recognizing and killing HLA-A2 Melan-A+ tumor lines but did not recognize Melan-A- 
cell lines. As before, tumor lysis was higher for ELA peptide (Luft et al. 2001).  
Tetramer Technology 
 The application of tetramer technology to ACT methods allows for quantification 
of the number of tumor antigen-specific lymphocytes. A tetramer assay can be used to 
detect and measure the number of T cells directed against a given antigen. The assay 
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takes into account that each TCR is specific for a select peptide and will bind with high 
affinity to the chosen peptide (Constantin et al. 2002). The tetrameric complex is 
generated using a central streptavidin molecule. The streptavidin molecule has the ability 
to form homotetramer complexes and has a high affinity for biotin. Genetically 
engineered MHC molecules with a biotinylated domain are mixed with the target peptide 
resulting in a central streptavidin molecule with four bound peptide-MHC complexes 
(Constantin et al. 2002). Once these complexes are added to the T cell culture, the T cell 
receptor specific for the peptide will bind. Unbound cells can be washed and removed 
and T-cells stained to be quantified.  
Cytokine release assays  
 A large majority of the studies analyzed in this paper utilized a cytokine affinity 
matrix to select for T cells that had specific effector functions and therefore were 
secreting specific cytokines. This method, developed by Manz et al , allows separation 
and sorting of cells based on the products they secrete. Previously, this was not a 
selection method that could be used as it was difficult to assign secreted products to a 
specific cell. In this case, the secreted product is retained on the cell surface allowing for 
easier detection. An affinity matrix specific for the product of interest is attached to the 
cell surface and cells are then stimulated in our case, with antigen. Cell secretion is 
allowed in a medium of low permeability for the secreted product, and these products are 
then stained as an artificial surface molecule. In several ACT studies, induction of IFNγ 
secretion was done by stimulating T cell lines with T2 cells that had been pulsed with a 
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specific peptide (Manz et al. 1995). IFNγ-positive T cells were then separated using 
magnetic cell sorting.   
Response Evaluation Criteria In Solid Tumors (RECIST)  
 RECIST is considered an internationally defined set of guidelines that can be used 
to standardize the response of a tumor to any treatment in patients. Specific criteria 
classify tumor response, stabilization, or progression. The criteria were spearheaded by a 
collaboration of the National Cancer Institute of the U.S. and that of Canada, as well as 
the European Organization for Research and Treatment of Cancer.  
 In order for researchers performing studies measuring responses to treatment to 
use RECIST guidelines, eligibility must first be met. Eligibility is classified as patients 
who have measurable disease at baseline, wherein the term ‘measurable disease’ refers to 
the presence of at least one measurable lesion. A measurable lesion defined as one that 
can be accurately measured in one dimension with diameter at least 20mm by X-ray or 
diameter of 10mm by CT scan or caliper measurement. Criteria for tumor response 
evaluation will be presented but other criteria will not be mentioned further.  
  Tumor response evaluation criteria are separated into four response categories:  
 Criteria 
Complete Response (CR) 
Disappearance of target lesions and reduction of 
pathological lymph nodes (<10mm) 
Partial Response (PR) 
A minimum decrease of 30% in the sum of diameters (based 
on baseline sum measurement) 
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Stable Disease (SD) No shrinkage or increase (using smallest sum as reference)  
Progressive Disease (PD) 
A 20% increase in the sum of diameters of target lesions 
(using the smallest sum as a reference point) AND an 
increase of at least 5 mm  
 
 Finally, studies also use RECIST guidelines to evaluate overall response to 
treatment. This response takes into account the total patient response from the beginning 
to the end of treatment, the findings on both target and non-target disease, and the 
presence and appearance of new lesions. Determination of best overall response for 
studies that require classification of CR or PR is based on criteria being met at a 
subsequent point in time. For example, if at an initial point in time, the response was 
noted as CR and at a later point in time is noted as SD, then the best overall response will 
be classified as SD. Duration of overall response is defined as the time from when criteria 
for CR/PR is met until the first date of recurrence or progression.  
Common Terminology Criteria In Adverse Events (CTCAE)  
 The CTCAE are national criteria published by the National Cancer Institute which 
standardize any adverse reactions to drugs or therapies with most the recent version 
(4.03) published in 2010. CTCAE classifies an adverse event (AE) as “any unfavorable 
and unintended sign, symptoms, or disease temporarily associated with the use of a 
medical treatment or procedure…” The grading scale is from 1 – 5 with 1 being the least 
severe and 5 representing any death related to an AE. Grading criteria are listed 
separately for each physiological or anatomical system listed as System Organ Class 
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(SOC). A sample CTCAE for classification of cytokine AE under Immune Disorders is 
shown below.  
 
Adverse 
Event 
1 2 3 4 5 
Cytokine 
Release 
Syndrome 
Mild 
reaction; no 
infusion 
interruption; 
intervention 
not indicated 
Therapy/Infusion 
interruption 
indicated, etc. 
Prolonged 
recurrence of 
symptoms 
following 
initial 
improvement 
Life-
threatening 
consequences, 
etc. 
Death 
 
A. ESTABLISHING AND EXPANDING CELL CULTURES 
Developing a method to identify and culture tumor-specific T cells has been a difficult 
process due to the smaller in vivo pool of T cells with tumor-specific antigens, but also 
because methods used to generate larger pools of T cells have been variably successful. 
The previous discussion on regression and data regarding immune reactions at tumor sites 
establishes that therapeutic techniques utilizing tumor-infiltrating lymphocytes hold 
promise as a target-specific regimen for melanoma. The next step required was 
measurement of the pool of available T cells within tumor sites.  
Generation of tumor-infiltrating lymphocytes begins with the resection of 
melanoma tumor lesions and establishing cultures in vitro from digested tissue fragments. 
Figure 6 illustrates the methods used to culture lymphocyte cell lines. Multiple lines per 
patient are cultured in media with IL-2 to stimulate initial growth (Yang and Rosenberg 
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2016). The general growth period for this phase is 2 to 3 weeks at which point TIL 
cultures reach cell populations of several millions. The range of cells varies from 10^8 to 
10^9. Cultures can then be further expanded using a rapid expansion protocol (REP) with 
increases up to a 1000 fold (Yang and Rosenberg 2016). Stimulation via REP uses anti-
CD3 (more common) and/or anti-CD28 monoclonal antibodies with IL-2. These methods 
help offset the initial low number of tumor antigen-specific T-cells since melanoma cells 
are poorly antigen-presenting and are not strongly antigenic. Once cultures are complete, 
cytokine assays can then be used to determine activity and specificity of lymphocytic 
lines.    
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Figure 6: Illustration of adoptive cell transfer (culture to infusion).  
The figure above represents two techniques, autologous cell transfer or 
genetically modified transfer that are currently under study for the treatment of 
multiple cancers.  
Source: (Phan and Rosenberg 2013)  
 
 
Generation of cell cultures  
Dudley et al. examined three different methods of deriving tumor-infiltrating 
lymphocyte cell cultures and the efficacy in generating cell populations of each 
technique. Tumor-infiltrating lymphocytes can be derived from tumor fragments, single-
cell digests, or physical disaggregation of melanoma tissue fragments. The tumor 
fragment method cuts chunks of specimen into 1-2 cm pieces and each fragment is then 
placed in a well and cultured. Single-cell digests go a step further and incubate the 
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fragments in a slurry of enzymes such as collagenases, hyaluronidases, and DNases. 
Finally, physical disaggregation involves mechanical shear force generated by a device 
called a Medi-machine to break up tumor tissue. Cultures can then be examined for 
specificity and activity using cytokine assays. Many lymphocytes were stimulated with 
tumor cell lines or an aliquot of single-cell tumor digests in order to identify and isolate 
tumor antigen-specific lymphocytes.T2 cells that lacked the TAP transporter, were pulsed 
with melanoma antigens that could be internalized and presented. These T2 lines were 
measured for IFNγ secretion measured with cytokine assays to sort effector function 
specific cells.  
PBMC feeder cells were obtained from  normal donors, treated with anti-CD3 
antibodies and IL-2 to activate the cultures (REP). These PBMC feeder cells are 
important in generating mononuclear cells (Raulf-Heimsoth 2008). In this case, the REP 
creates an environment where these mononuclear cells can be exposed to a selected 
antigen to generate specificity (Raulf-Heimsoth 2008). After 14 days, cells were 
harvested and prepared for patient treatment. In all three cases, cultures were obtained 
from greater than 90% of patients, however, in examining the expansion rate of cultures 
per method, we find that tumor fragments resulted in expansions of 69.9% whereas 
single-cell digests and physical disaggregation yielded greater than 90% expansion 
(Dudley et al. 2003).  
Analysis of antigen activity and specificity was performed on these cell cultures 
after stimulation by HLA-A2 tumor cells and analysis of respective cytokine secretion. 
TILs were screened from 36 patients to measure specificity against tumor antigens and 
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83% were found to have detectable activity against melanoma tumor cell targets (Dudley 
et al. 2003). Additionally, analysis of TILs from a single tumor found that there is a 
varying pattern of antigen recognition within the cells. Further examination of multiple 
cell cultures from a single tumor specimen also found significant variation in the 
frequency of CD4+ T cells with CD4+ cells ranging anywhere from 19% to 70% of total 
cells (Dudley et al. 2003). Once cultures with tumor-reactive TILs were identified, cells 
were expanded by administration of IL-2which led to an average cell population of 3 x 
10^7 (Dudley et al. 2003). These expanded cells served as the preliminary cell lines for 
patient treatment. Subsequent application of REP expanded the cell population 1320 fold 
(4x10^10) in 14 days(Dudley et al. 2003). Thus, 13 TIL cultures from 8 patients were 
expanded for the purpose of patient treatment.  
Sporn et al. combined chemotherapy and adoptive immunotherapy by 
administering cyclophosphamide previous to adoptive transfer, however, these early 
results were variable. (Sporn et al. 1993). Blood lymphocytes were isolated from 14 
patients, cultured with irradiated autologous tumor cells for the purpose of antigen-
recognition and IL-2 to stimulate growth and then returned to the respective patients 
along with administration of IL-2 intravenously. Lymphocytes were primarily CD4+ cells 
and although they exhibited variable degrees of cytotoxicity, therapeutic responses were 
low despite previous NCI trials exhibiting a 20% response in melanoma cases in similar 
studies (Sporn et al. 1993). Lack of T cell specificity for tumor antigen, as well as 
difficulty in assessing the strength of lymphocyte response, were noted as primary 
hurdles in achieving strong therapeutic responses.  
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Although adoptive cell transfer shows promise, it has been hindered by difficulty 
in extraction and isolation of antigen-specific T cell populations. Early techniques 
utilized polyclonal T cells (tumor infiltrating lymphocytes) after IL-2 expansion. Once 
melanoma-specific antigens were able to be identified and specifically targeted, T cells 
that were antigen-specific could be specifically selected. This technique is particularly 
promising for late stage metastatic melanoma.  
Later, Oelke et al. and Maidenbauer et al. attempted to quantify T cells that were 
tumor antigen specific by utilizing tetrameric technology and flow cytometry cytokine 
analysis. Oelke et al. used CD8+ T-cells from healthy donors and stimulated them with 
Melan-A autologous dendritic cells in order to generate tumor antigen-specific T cells. 
The study attempted to devise a method for expansion of T cells that were specific and 
cytotoxic, and that could generate large concentrations in a reasonable time frame. In 
vitro generation was done using monocytes along with granulocyte macrophage colony-
stimulating factor (GM-CSF) with addition of IL-4 and TGFβ1. After 3 to 4 weekly 
stimulation cycles, in vitro, CTL responses were determined. The frequency of 
CD8+/Melan-A T-cells was measured using tetramer analysis and found to be 3.5% 
(Oelke et al. 2000). Cells were subsequently stimulated with monoclonal antibodies 
against CD3 and CD28, and with IL-2 which led to a 600-fold expansion (Oelke et al. 
2000). Cell testing confirmed specificity for Melan-A and ability to lyse Melan-A 
positive melanoma cells (Oelke et al. 2000). 
Further studies were done to establish a protocol for the number of stimulation 
cycles necessary for optimal T cell population counts. Cycle numbers were tested using 
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influenza antigen and the results of the study applied when generating Melan-A specific 
T-cells. Results found that T cells undergoing three cycles had high toxicity for target 
antigen, but did not lyse unlabeled T2 cells or T2 cells with irrelevant peptides (Oelke et 
al. 2000). Those that had undergone cycles below three were often cytotoxic, but lacked 
specificity. Initial response resulted in a 40-fold increase in populations (Oelke et al. 
2000).  
 A second set of conditions where cells, after four cycles of stimulation, were 
subjected to the rapid expansion protocol (REP). Addition of anti-CD3 and anti-CD28 
monoclonal antibodies supplemented with IL-2 resulted in a further 15-fold increase in 
cell concentrations (Oelke et al. 2000). Cell lines were either directly obtained from 
PBMC or after 5 weeks in vitro and their specificity was measured using TM technology. 
Cell lines that were not stimulated using the REP had lower T-cell frequencies (0.01% to 
0.48%)  while the range for those T-cells that were cultured increased from to 3.42% 
(Oelke et al. 2000).  
Oelke’s study showed that antigen-specific CTLs can expand up to 600-fold with 
initial antigen-specific and later nonspecific stimulation. In terms of timing, induction of 
CTLs using this method might have better implications for treatment time since cultures 
take about 4 to 5 weeks to be sufficient in number. In contrast, previous methods of 
expansion using CTL clones often required up to 2 months or more of in vitro culturing 
(Oelke et al. 2000). While the study showed promise in quantifying and creating a 
methodology for cell cultures, it did not address the lack of CD4+ helper cells to produce 
an antitumor immune response. Oelke hypothesizes that this could be overcome with 
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further IL-2 and IL-12 administration, however these cytokines also generate cytotoxic 
responses and no study has measured their effectiveness in CD4+ tumor responses. A 
second solution would require co-administration of melanoma specific CD4+ T-cell lines. 
In this study, a second limiting factor is that the selection for only one antigen can be 
detrimental if tumors mutate so that the target antigen is no longer recognized by T cells 
or “hide” target antigen. It is thought that polyclonal antigen-specific T cells could 
overcome this detriment but at the expense of longer cell culture timing.  
 This poses a separate issue of culture timings and its effect on responses to ACT. 
A 2010 study compared TILs that had been cultured for a shorter time respective to the 
usual 6 to 8 week period and found that patient responses were better. Besser et al. notes 
these TIL as “Young-TIL” to classify them separately and stated that unlike previous 
studies, there was no restriction for HLA-A2. Normally, this restriction is important as 
previous studies have noted the importance of HLA-A2 expression for the tumor 
recognition by autologous lymphocytes. Besser et al. however, noted that this restriction, 
in conjunction with longer incubation times and IFNγ selectivity, often leads to high 
exclusion rates of enrolled patients. Specifically, a fair amount of patients who are 
initially enrolled lack HLA-A2 expression and are subsequently removed from trial data. 
They hypothesize that other criteria such as culture time and telomere length of the T-
cells may be more useful for predicting therapeutic response while simultaneously 
allowing a larger patient population to participate in experimental trials.  
 Previous studies have found a correlation between telomere length and response 
efficacy (Shen et al. 2007). Generally, longer telomeres are found in Young-TIL cultures 
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which can be generated in two weeks and often require simpler procedures than those 
mentioned above. Young-TIL can be established using one bulk T cell culture, therefore 
cells spend less time in culture and can be expanded in a shorter amount of time. In this 
case however, cytokine assays and selection was removed from protocol. Initial studies 
with eight patients found that there was one complete response, two partial responses, 
and four patients had disease stabilization (Besser et al. 2009). A subsequent phase II trial 
was initiated with 20 patients with stage IV melanoma, who underwent lymphodepletion 
followed by transfer. These patients were administered cyclophosphamide and 
fludarabine a week in advance of TIL infusion. Young-TIL were administered followed 
by IL-2. 10 of the 20 experienced an objective response as classified by RECIST with 2 
complete and 8 partial remissions (Besser et al. 2010). Those with complete response had 
ongoing remission at four and 20 months (Besser et al. 2010). Of those who did not 
respond, four experienced disease stabilization and six had disease progression. Young-
TIL were generated in 90% of patients and patients who responded to treatment had a 
median survival increase of 10 months (Besser et al. 2010).  
 
B. LYMPHODEPLETION PRIOR TO ADOPTIVE TRANSFER 
Several studies have found that lymphodepletion via either chemotherapy or radiation 
facilitates a stronger response to ACT in melanoma patients. Phase I initial studies at the 
NCI measured patient response rates following a lymphodepletive pre-treatment regimen 
along with ACT generated a 47% response in an early trial of 13 patients (Dudley et al. 
2005). Follow-up trials conducted by Dudley et al. with 35 patients achieved an objective 
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response rate of 51% (Dudley et al. 2005). The results showed three complete responses 
and fifteen partial responses. Regression was seen at multiple sites including cutaneous 
sites, liver metastasis, and brain. Standard dosages of cyclophosphamide (60mg/kg) were 
given for 2 days followed by cell infusion with IL-2. Development of autoimmune events 
was noted in a small subset of patients who were diagnosed with vitiligo or uveitis.  
Later studies by Rosenberg et al. compared response rates to ACT with prior 
chemotherapy administration or with prior chemotherapy accompanied by radiation (2 
Gy or 12 Gy). In this case, chemotherapy consisted of cyclophosphamide and 
fludarabine. Radiation therapy was delivered I n 2-Gy fractions with 15-MV photons at a 
dose of 0.11Gy/min (Dudley et al. 2008). Objective response rates were found to be 
highest in cases where high radiation was administered in conjunction with chemotherapy 
at 72% (Steven A. Rosenberg and Dudley 2009). 93 patients were enrolled and three 
consecutive protocols were established. The first protocol, consisting of 43 patients, was 
administered chemotherapeutic drugs as mentioned above followed by ACT. The second 
group of 25 patients was given chemotherapy followed by 200cGy TBI before ACT. A 
final group of 25 was administered TBI of 1200cGy with all other variables remaining 
the same. Response rates were 49%, 52%, and 72% respectively and many patients had 
ongoing responses at the three year mark (Steven A. Rosenberg and Dudley 2009). Since 
these trials were consecutive however, it is difficult to positively conclude if a direct 
increase in TBI leads to an increased response rate. Despite this, lymphodepletion by 
addition of total body irradiation (TBI) was found to increase anti-tumor effects. Studies 
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in mouse models have suggested that the reason for this response is a result of two 
immunological mechanisms: 
i) Elimination of regulatory T cells 
Regulatory T cells can develop in the thymus or peripheral tissues and inhibit the 
activation of lymphocytes that target self antigens. Most of these regulatory T cells are of 
the CD4 variety and express increased levels of CD25. It has been found that a decrease 
in the total number of CD4+ T cells enhances adoptive transfer therapy against tumor or 
self antigen (Antony and Restifo 2005). Physiologically, CD4+ T cells facilitate the 
response of CD8+ T cells against viral or foreign antigens (Antony and Restifo 2005). 
The subset of CD4 cells (CD4+ CD25+ T regulatory cells) work to suppress T cells and 
control tolerance to self-antigens (Gattinoni et al. 2005). Removal of these regulatory T 
cells often correlates with increased autoimmune destruction (Gattinoni et al. 2005). 
Therefore it is hypothesized that removal of T regulatory subsets while inherently 
problematic due to development of autoimmunity, may also help facilitate a stronger 
response to adoptive transfer. This autoimmune response was found in the previously 
mentioned patient populations where a small group of individuals developed antibodies 
to melanocytes and later developed vitiligo.   
 
ii) Cytokine competition for lymphocyte growth 
Initially, elimination of CD4+CD25+ T regulatory cells was believed to the be main 
reason that lymphodepletion helped facilitate anti-tumor responses however, Gattinoni et 
al. found that patients with genetic loss of regulatory T cells still saw benefit with 
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lymphodepletion prior to ACT. Follow-up studies found that chemotherapeutic regimens 
helped to remove cytokine competition for transferred lymphocytes (Gattinoni et al. 
2005). IL-7 and IL-15 normally help enhance T-cell function and removal of other 
competing cells that would “use up” cytokines helped to keep these interleukins available 
for growth of transferred cells (Gattinoni et al. 2005). It had been hypothesized that NK 
cells may serve as sinks for IL-15. Mouse models with melanoma were used to measure 
the response to ACT. Tumor area and size measurement was used to gauge strength of 
response. Experiments with Rag1-/- mice  which lack both B and T cells, but have NK 
cells, found that irradiation improved TIL response against tumor cells (Gattinoni et al. 
2005). Therefore, irradiation removed NK cells which would normally utilize IL-15 and 
increased availability of the cytokine for TILs. Additionally, administration of  
monoclonal antibodies towards NK IL-15 receptors confirmed this theory as it led to an 
increased response similar to that of irradiation treatment. A second experimental study 
using Rag2-/-/γc mice which lack B, T, and NK cells was done. In this case, mice that 
were lacking these cells did not differ in response with mice that were subjected total 
body irradiation since they had no immune  cells to compete for TIL cytokines (Gattinoni 
et al. 2005).  
 
C. INTRAVENOUS ADMINISTRATION WITH IL-2 
Yee, et al. also compared the efficacy of autologous T cell injections with varying 
levels of IL-2. Patients with stage IV melanoma were injected with TIL and no initial IL-
2 and IL-2 infusions administered were slowly increased from 0.25x106 units/m2 to 1x106 
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units/m2 twice daily for 14 days (Yee et al. 2002). Therefore, IL-2 dosage was increased 
every 2 weeks. 10 patients were administered therapy and no serious toxic events were 
noted. Infusions given without IL-2 were noted to have significantly lower median 
survival and frequency of T cells was on average less than 0.01% by day 14 as measured 
by PCR and tetramer technology. In contrast, infusions that were given with low dose IL-
2 had a frequency that did not go below 0.01% until day 21 (Yee et al. 2002). Il-2 dosage 
varied consecutively from 0.5, 1, and 2 million units/m2, however, after 0.5 the responses 
to a higher IL-2 dosage did not show a significant change in frequency or median 
survival, defined as the day on which one-half maximal frequency of T-cell during 
tetramer analysis (Yee et al. 2002). Median survival of T cell clones with zero IL-2 was 
found to be on average 6.68 whereas those with IL-2 had a median survival of 16.92 (Yee 
et al. 2002).  
Studies like the one above described the use of interleukin-2 as a potent cytokine that 
can be utilized for expansion of T cells in several cancer regimens. Combination of Il-2 
regimens with adoptive cell transfer is now standard as it was proven effective in both 
mouse models and human trials. Major toxic side effects were mentioned previously but 
will be elaborated here as well. Patient symptoms included malaise, nausea, vomiting, 
hypotension, fluid retention, and organ dysfunction.  
 A pilot trial by Ellabaek studied the importance of IL-2 dosage and postulated that 
low dose IL-2, as opposed to levels normally administered during ACT, can be as 
effective and sidestep cytokine related adverse events. Lymphodepletion was 
administered approximately a week before TIL were intravenously infused and was 
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followed by 14 days of IL-2 injections of 6000 IU/mL. Responses were monitored using 
CT and PET scans and assessment was done using RECIST guidelines.  
 Six patients with metastatic melanoma were treated using this new protocol. Of 
these, two patients had a complete response and two patients had stable disease (Ellebaek 
et al. 2012). One patient had brain metastasis and disease had spread to lymph nodes of 
the pelvis. Prior to therapy, brain metastasis and one pelvic nodule were surgically 
removed. Therapy slowed the regression and after 1.5 years, PET scanning was negative 
in both sites. The patient continued to be in remission at the 30-month mark (Ellebaek et 
al. 2012). The second patient with complete response had metastases to the neck and 
cheek which were removed prior to therapy. Post-therapy the patient continued to be in 
remission after 10 months (Ellebaek et al. 2012) .  
 IL-2 toxicity was labeled at grade 3-4 (CTCAE) and was mainly related in this 
study to the lymphodepletion chemotherapy and consisted of GI symptoms, fatigue, and 
low blood cell counts. Patients were noted to have grade 2 anemia and received blood 
transfusions, and exhibited leucopenia, neutropenia, and lymphopenia as well (Ellebaek 
et al. 2012). TIL infusion symptoms manifested mainly as fever and chills. A smaller 
subset of patients had high blood pressure and tachycardia. Il-2 administration resulted in 
grade 2 nausea and fatigue as well as chills in the initial hours after injection.  
 
DISCUSSION 
 
 Metastatic melanoma, particularly Stage IV melanoma, has a low 1-year survival 
rate and is one of the most common causes of cancer death, especially in the West. 
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Normally, T cells that are tumor antigen-specific are low, however, adoptive transfer 
allows ex vivo proliferation and manipulation of autologous lymphocytes to significantly 
improve specificity and response.  
Peptide targets have been useful in maintaining T cell specificity however, 
expression of MART-1 and gp100 can also be found in some normal tissues leading to 
autoimmune reactivity. This, coupled with removal of regulatory cells, could lead to 
serious immunological consequences if not monitored and resolved. Additionally, T cell 
targeting of normal tissue cells takes away from a total anti-tumor response.  
Another new technology is utilizing genetic modification of the T cell receptor or 
T cell characteristics to produce tumor-specific T cells. The majority of this thesis has 
focused on tumor-specific T cells found in the blood and tumor tissue, however, as 
briefly mentioned, the introduction of peptide antigens via dendritic cells or endocytotic 
uptake and presentation has also shown promise.  
In terms of ACT expansion, which has been one of the major hindrances to wider 
applications, technological advances have now reached a point where sorting and 
selecting for T cell specificity is faster than in the past. Bernatchez elucidates new cell 
sorting technology such as the MACSQuant Tyto and Miltenyi which uses tetramer 
technology to separate cells. Further effectiveness of ACT as a therapeutic requires T cell 
specificity and differentiation that is both quick and efficient to meet patient demands. 
Though ACT responses have been more significant than any previous therapeutic, neither 
culture growth nor response is guaranteed for all patients.  
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More than 400 melanoma patients alone have received TIL therapy and responses 
have been promising (Bernatchez et al. 2016). In addition, ACT has been used for the 
treatment of other cancers such as ALL, ovarian, and colorectal cancer. A major 
limitation, as alluded to previously, is the ability to expand cells rapidly and with the 
necessary specificity. A method or machine to help eliminate the laborious process will 
be crucial to the use of ACT in hospitals nationally and internationally. Studies by Besser 
et al. addressed this issue by reducing culture time of TIL and streamlining the procedure. 
However, this comes at the expense of removing HLA restriction and although the study 
found a clinical response, the patient sample size was small and further studies will be 
needed before its efficacy can be established.  
Next steps in the advancement of these types of regimens will require further 
knowledge about the characteristics of tumor cells, the phenotypes of immune cells, and 
the ability to manipulate and modify these cells to generate effective and long-standing 
responses. This process includes identifying and isolating new tumor biomarkers and the 
generation of T cells with specificity for multiple tumor antigens. Administration of a 
combination of both immunotherapy with standard therapy could play a significant role 
in preventing tumor evasion of immune response and improvement of therapeutic 
response.  
Despite the technical and physiological hurdles of adoptive transfer, the therapy is 
promising not only for metastatic melanoma but also for its potential applications in the 
treatment of other cancers. Current therapeutics in melanoma have had variable success 
rates with responses in late stage cancer. Currently checkpoint blockade and other 
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immunotherapies are at the forefront of melanoma research. Numerous studies have 
found greater responses for late stage cancer in adoptive cell transfer in comparison to 
other available therapies. Adoptive cell transfer therapy is one more step in the movement 
of medicine towards a more targeted and personalized forms of therapy. As this demand 
for personalized medicine increases, technology will increase, and the availability of such 
treatments has the potential to become more mainstream.   
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